Jane Holmes Hollingsworth is managing partner of Militia Hill Ventures, a fund focused on growing high-quality life sciences companies, and executive chair of Immunome Inc., a cancer immunotherapy company. Jane is also co-founder and former CEO of NuPathe Inc., a publicly traded biopharmaceutical company focused on diseases of the central nervous system and sold to Teva Pharmaceuticals in 2014. She is also the co-founder and former EVP of Auxilium Pharmaceuticals, a publicly traded specialty pharmaceutical company based in Malvern, PA.
Prior to founding and launching two successful biopharmaceutical companies, Jane was vice president, secretary, and general counsel of IBAH, Inc., a publicly traded, multinational clinical research organization. Before joining IBAH, she practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.
Jane is one of the leaders of the entrepreneurial and life sciences communities, serves as the president of the Alliance of Women Entrepreneurs (AWE), and sits on various industry and community boards, including AWE, the University City Science Center, the Kimmel Center for the Performing Arts, the Wilma Theater, and Breastcancer.org.